If existing gene editing approaches are like “scissors” that cut the genome, base editors are “pencils” that enable erasing and rewriting one letter of the genome at a time.Our team and culture are central to building an organization that we are all proud of and one that will allow us to realize our vision of providing life-long cures for patients suffering from serious diseases. A change to a single letter, known as a point mutation, can mean the difference between health and disease. Beam Therapeutics, a preclinical biotech developing therapies based on single-base gene editing, raised the proposed deal size for its upcoming IPO … © 2007-2020, Xconomy, Inc.Xconomy is a registered service mark of Xconomy, Inc.All rights reserved.Beam filed IPO paperwork with securities regulators back in September. Companies; Documents; Forms; Alerts; Stock Ticker Lookup. Our culture is an essential component to maintaining our competitive long-term advantage.The foundational level of our genetic information is a single base in our DNA. Our depth of expertise in base editing and drug discovery, along with the considerable academic and research expertise of our founders and our exclusive licenses to novel technologies, positions us at the forefront of the field of advanced precision genetic medicines.– MGTA-117 conditioning for precise depletion of cells in the bone marrow could potentially increase patients’ benefit from Beam’s base editing therapies for sickle cell disease and beta thalassemia – CAMBRIDGE, Mass. He/She will support our exploratory research Read More. Beam, which was slated to begin trading Thursday on the Nasdaq exchange under the stock symbol “BEAM,” sold 9.25 million shares, up from the 6.25 million it said it planned to […]Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medicationsThe company’s debut comes amid a busy time for the life sciences sector in the public markets.Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research We have attracted a talented team of industry experts and scientists as part of our high performing team. Beam Therapeutics has filed to raise $100 million in a U.S. IPO. General Information: Business: We are a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases. --(BUSINESS WIRE)--Jun. About Form S-1 . Beam Therapeutics is seeking a highly talented and motivated Head of Chemistry with expertise in oligo synthesis, nucleic acids and Read More. We are currently seeking a self-motivated and technically competent scientist to join our team. ET on Seeking Alpha. Print. By using base editors to rewrite a single letter of the genome, Beam has the potential to create life-long cures for patients suffering from serious diseases. Sarah de Crescenzo. d734398ds1.htm S-1 Zoom In Zoom Out. Form S-1 Beam Therapeutics Inc. General form for registration of securities under the Securities Act of 1933.
The firm is advancing genetic treatments for various diseases. Beam Therapeutics. SEC.report. Base editors have the ability to rewrite just a single letter, and thereby intervene at the most foundational level to treat a wide range of diseases. Search / Go.
The company is one of a number in the gene-editing arena working to develop a CRISPR-based technology that can offer even more precise genomic edits.Join us on July 16 for a special two-part gathering that will take a unique and critical look at the Internet today, and where it is heading.The indications it aims to tackle are broad, including the blood disorders sickle cell disease and beta thalassemia; T-cell acute lymphoblastic lymphoma and acute myeloid leukemia in oncology; liver diseases, including alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and Stargardt disease, an interited form of macular degeneration, and other ocular and central nervous system disorders.Top biotech and investment players offer their best plans and current progress in stemming and ultimately defeating the worldwide pandemicFrom Our Editors · Special ReportBeam’s largest stockholders following the IPO are Arch Venture Partners, which owns 17 percent of Beam’s shares, and F-Prime Capital, which owns 14.4 percent.
Beam Therapeutics sets IPO terms Jan. 27, 2020 at 10:55 a.m. Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered. Using this toolkit of approaches, we are advancing a broad, diversified portfolio of 12 base editing programs against distinct editing targets and diseases.We are continuing to build a strong, values-driven organization focused on our people, advancing cutting-edge science, and rigorously developing a new class of precision genetic medicines. Beam Therapeutics Inc. Form S-1 (Filer) Published: 2019-09-27 16:34:21 Submitted: 2019-09-27. March 18, 2020 Scientist I/II, In Vivo Liver Biology.
The most common class of genetic mutations are errors of a single base, known as point mutations. BEAM IPO Price: (view offering) | BEAM IPO Date: February 6, 2020 | Industry: Biotechnology | View info for the Beam Therapeutics IPO at ClickIPO.
Beam Therapeutics Inc. Form S-1.